National Mammography Quality Assurance Advisory Committee; Notice of Meeting, 44662 [05-15373]

Download as PDF 44662 Federal Register / Vol. 70, No. 148 / Wednesday, August 3, 2005 / Notices IV. Submission of Comments Interested persons may submit written or electronic comments to the Division of Dockets Management (see ADDRESSES). Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. You can also view received comments on the Internet at https://www.fda.gov/ ohrms/dockets/dockets/dockets.htm Dated: July 28, 2005. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 05–15282 Filed 8–2–05; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration National Mammography Quality Assurance Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. Name of Committee: National Mammography Quality Assurance Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues. Date and Time: The meeting will be held on September 26 and 27, 2005, from 9 a.m. to 6 p.m. Location: Holiday Inn, Walker/ Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD. Contact Person: Charles Finder, Center for Devices and Radiological Health (HFZ–240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301–594–3332, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512397. Please call the Information Line for up-to-date information on this meeting. Agenda: The committee will discuss the following issues: VerDate jul<14>2003 15:22 Aug 02, 2005 Jkt 205001 (1) Regulatory and nonregulatory mechanisms to enhance mammography quality while reducing the regulatory and inspection burden on facilities; (2) Recommendations made by the Institute of Medicine regarding the current Mammography Quality Standards Act (MQSA) program, interventional mammography, and nonmammographic breast imaging procedures; and (3) All relevant guidance documents issued since the last meeting. The committee will also receive updates on recently approved alternative standards, voluntary stereotactic accreditation programs, and the radiological health program. MQSA regulations and guidance documents are available to the public on the Internet at https://www.fda.gov/cdrh/ mammography. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 5, 2005. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10:30 a.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 5, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Shirley Meeks at 240–276–0450, ext. 105, at least 7 days in advance of the meeting. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: July 27, 2005. Sheila Dearybury Walcoff, Associate Commissioner for External Relations. [FR Doc. 05–15373 Filed 8–2–05; 8:45 am] BILLING CODE 4160–01–S PO 00000 Frm 00110 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Indian Health Service Request for Public Comment: 60-Day Proposed Information Collection: Indian Health Service Loan Repayment Program SUMMARY: The Department of Health and Human Services, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)). This program helps to ensure that requested date can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Indian Health Service (IHS) is providing a 60-day advance opportunity for public comment on a proposed extension of current information collection activity to be submitted to the Office of Management and Budget for review. Proposed Collection: Title: 0917– 0014, ‘‘Indian Health Service Loan Repayment Program.’’ Type of Information Collection Request: Extension, without revision, of currently approved information collection, 0917– 0014, ‘‘Indian Health Service Loan Repayment Program.’’ Form Number: None. Forms: The IHS Loan Repayment Program Information Booklet contains the instructions and the application formats. Need and Use of Information Collection: The IHS Loan Repayment Program (LRP) identifies health professionals with pre-existing financial obligations for education expenses that meet program criteria and who are qualified and willing to serve at, often remote, IHS health care facilities. Under the program, eligible health professionals sign a contract under which the IHS agrees to repay part or all of their indebtedness for professional training education. In exchange, the health professionals agree to serve for a specified period of time in IHS health care facilities. Eligible health professionals that wish to apply must submit an application to participate in the program. The application requests personal, demographic and educational training information, including information on the educational loans of E:\FR\FM\03AUN1.SGM 03AUN1

Agencies

[Federal Register Volume 70, Number 148 (Wednesday, August 3, 2005)]
[Notices]
[Page 44662]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15373]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


National Mammography Quality Assurance Advisory Committee; Notice 
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: National Mammography Quality Assurance Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 26 and 27, 
2005, from 9 a.m. to 6 p.m.
    Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact Person: Charles Finder, Center for Devices and Radiological 
Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., 
Rockville, MD 20850, 301-594-3332, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 3014512397. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: The committee will discuss the following issues:
    (1) Regulatory and nonregulatory mechanisms to enhance mammography 
quality while reducing the regulatory and inspection burden on 
facilities;
    (2) Recommendations made by the Institute of Medicine regarding the 
current Mammography Quality Standards Act (MQSA) program, 
interventional mammography, and nonmammographic breast imaging 
procedures; and
    (3) All relevant guidance documents issued since the last meeting.
    The committee will also receive updates on recently approved 
alternative standards, voluntary stereotactic accreditation programs, 
and the radiological health program. MQSA regulations and guidance 
documents are available to the public on the Internet at https://
www.fda.gov/cdrh/mammography.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by September 5, 
2005. Oral presentations from the public will be scheduled between 
approximately 9:30 a.m. and 10:30 a.m. on both days. Time allotted for 
each presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before September 5, 
2005, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Shirley Meeks at 
240-276-0450, ext. 105, at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: July 27, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External Relations.
[FR Doc. 05-15373 Filed 8-2-05; 8:45 am]
BILLING CODE 4160-01-S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.